Michael Mellon, MD Journal of Allergy and Clinical Immunology

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis William R. Lumry, MD Journal of.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

Asthma diagnosis and treatment: Filling in the information gaps

Richard L. ZuWallack, MD a,b, James P

Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma Patrick Booms, MSca, David.

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial Pierluigi Paggiaro,

Safety and efficacy of mometasone furoate aqueous nasal spray in children with allergic rhinitis: Results of recent clinical trials Javier Dibildox,

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

David P. Skoner, MD, Betty L

Badrul A. Chowdhury, MD, PhD

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial William Busse, MDa,

The impact of allergic rhinitis on bronchial asthma

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Lawrence F. Eichenfield, MD, Lisa Beck, MD

Side effects of inhaled corticosteroids

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients.

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Peter König, MD, PhD Journal of Allergy and Clinical Immunology

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

A methodological assessment of diurnal variability of peak flow as a basis for comparing different inhaled steroid formulations John H. Toogood, MD,

A review of the current guidelines for allergic rhinitis and asthma

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Circadian variation of sputum inflammatory cells in mild asthma

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

New devices for asthma Journal of Allergy and Clinical Immunology

Efficacy of nebulized budesonide in treatment of severe infantile asthma: A double-blind study Jacques de Blic, MDa, Christophe Delacourt, MDa, Muriel.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Effects of β2-agonists on airway tone and bronchial responsiveness

Exercise-induced bronchoconstriction in children: Montelukast attenuates the immediate-phase and late-phase responses Raul E. Melo, MD, Dirceu Solé,

Peter S. Creticos, MD Journal of Allergy and Clinical Immunology

Clinical need for a nebulized corticosteroid

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Clinical effects of nedocromil sodium on challenges invoking neuronal mechanisms and on virally induced symptoms Peter König, MD, PhD Journal of Allergy.

Therapeutic strategies to reduce asthma exacerbations

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation Anthony P. Sampson, PhDa, Emilio Pizzichini, MD, PhDb,

Stanley J. Szefler, MD, Richard J

The Editors' Choice Journal of Allergy and Clinical Immunology

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Leukotriene receptor antagonists in asthma therapy

Corticosteroids in the treatment of pediatric allergic rhinitis

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Eckard Hamelmann, MD, Eric D

Short course of systemic corticosteroids in sinonasal polyposis: A double-blind, randomized, placebo-controlled trial with evaluation of outcome measures

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Challenges in assessing outcomes for pediatric asthma

Larry C. Borish, MDa, Harold S

Budesonide Inhalation Suspension Versus Montelukast in Children Aged 2 to 4 Years with Mild Persistent Asthma Stanley J. Szefler, MD, Lars-Goran Carlsson,

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

The correlation between allergic rhinitis and sleep disturbance

Clinical relevance of inhaled corticosteroids and HPA axis suppression

Desloratadine: A new, nonsedating, oral antihistamine

Presentation transcript:

Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma Michael Mellon, MD Journal of Allergy and Clinical Immunology Volume 104, Issue 4, Pages S191-S199 (October 1999) DOI: 10.1016/S0091-6749(99)70061-8 Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 1 Mean change from baseline in nighttime asthma symptom scores over 12 weeks of double-blind treatment. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. (From Kemp JP, Skoner D, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999;83:231-9. By permission.) B , Patients whose asthma was previously treated with inhaled corticosteroids. (From Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension [Pulmicort Respules] in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998;102:789-96. By permission.) C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. (From Baker J, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide nebulizing suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999;103:414-21. Reproduced by permission of Pediatrics.) *P ≤ .05, †P ≤ .01, ‡P ≤ .001 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 2 Mean change from baseline in daytime asthma symptom scores over 12 weeks of double-blind treatment. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. (From Kemp JP, Skoner D, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999;83:231-9. By permission.) B , Patients whose asthma was previously treated with inhaled corticosteroids. (From Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension [Pulmicort Respules] in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998;102:789-96. By permission.) C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. (From Baker J, Mellon M, Wald J, Welch M, Cruz-Rivera M, Walton-Bowen K. A multiple-dosing, placebo-controlled study of budesonide nebulizing suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics 1999;103:414-21. Reproduced by permission of Pediatrics.) *P ≤ .05, †P ≤ .01, ‡P ≤ .001 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 3 Mean change from baseline in the number of days bronchodilators were used per 14 days for breakthrough asthma symptoms. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. B , Patients whose asthma was previously treated with inhaled corticosteroids. (From Shapiro G, Mendelson L, Kraemer MJ, Cruz-Rivera M, Walton-Bowen K, Smith JA. Efficacy and safety of budesonide inhalation suspension [Pulmicort Respules] in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol 1998;102:789-96. By permission.) C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. *P ≤ .05 and †P ≤ .01 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 4 Treatment failures as the result of worsening asthma. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. B , Patients whose asthma was previously treated with inhaled corticosteroids. C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. *P ≤ .05, †P ≤ .01, ‡P ≤ .001 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 5 Mean change from baseline in morning PEF (L/min) over the 12-week, double-blind treatment period in patients capable of consistently performing pulmonary function tests. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. B , Patients whose asthma was previously treated with inhaled corticosteroids. C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. *P ≤ .05, †P ≤ .01 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions

Fig. 6 Mean change from baseline in FEV1 level (liters) over the 12-week, double-blind treatment period in patients capable of performing consistent spirometry. A , Patients whose asthma was not previously controlled with bronchodilators or noncorticosteroid anti-inflammatory agents. (From Kemp JP, Skoner D, Szefler SJ, Walton-Bowen K, Cruz-Rivera M, Smith JA. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol 1999;83:231-9. By permission.) B , Patients whose asthma was previously treated with inhaled corticosteroids. C , Patients whose asthma was previously treated with either bronchodilators or inhaled corticosteroids. *P ≤ .05 versus placebo. Journal of Allergy and Clinical Immunology 1999 104, S191-S199DOI: (10.1016/S0091-6749(99)70061-8) Copyright © 1999 Mosby, Inc. Terms and Conditions